TY - CHAP M1 - Book, Section TI - Pulmonary Pharmacolog A1 - Barnes, Peter J. A2 - Brunton, Laurence L. A2 - Chabner, Bruce A. A2 - Knollmann, Björn C. Y1 - 2015 N1 - T2 - Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 12e AB - Pulmonary pharmacology concerns understanding how drugs act on the lung and the pharmacological therapy of pulmonary diseases. Much of pulmonary pharmacology is concerned with the effects of drugs on the airways and the therapy of airway obstruction, particularly asthma and chronic obstructive pulmonary disease (COPD), which are among the most common chronic diseases in the world. Both asthma and COPD are characterized by chronic inflammation of the airways, although there are marked differences in inflammatory mechanisms and response to therapy between these diseases (Barnes, 2008b). After a brief introduction to asthma and COPD, this chapter discusses the pharmacotherapy of obstructive airways disease, particularly bronchodilators, which act mainly by reversing airway smooth muscle contraction, and anti-inflammatory drugs, which suppress the inflammatory response in the airways. This chapter focuses on the pulmonary pharmacology of β2 agonists and corticosteroids; the basic pharmacology of these classes of agents is presented elsewhere (Chapters 12 and 42). In presenting the details of pharmacotherapy of asthma and COPD, the chapter also covers the physiology and molecular pathology surrounding these conditions, deriving knowledge of the diseases by assessing their responses to various classes of drugs. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2023/09/28 UR - accessbiomedicalscience.mhmedical.com/content.aspx?aid=1127868850 ER -